Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study

Basit Öğe Kaydı
dc.contributor.authorKarhan, Ogur
dc.contributor.authorIleri, Serdar
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorArvas, Hayati
dc.contributor.authorKilic, Delyadil Karakas
dc.contributor.authorSezgin, Yasin
dc.contributor.authorErcek, Berrak Merit
dc.date.accessioned2025-02-22T14:08:50Z
dc.date.available2025-02-22T14:08:50Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate whether PPI use interferes with the efficacy of CDK4/6 inhibitors. Methods: This retrospective, multicenter, real-world study included 205 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patient data were collected from January 2020 to August 2023. Patients who received either ribociclib or palbociclib, with or without a PPI, were included. Median progression-free survival (mPFS) was estimated using the Kaplan-Meier method, and factors associated with mPFS were analyzed using Cox regression. Results: Among the patients, 100 received palbociclib and 105 received ribociclib. In the palbociclib group, 40 patients (40%) used a PPI, and 60 (60%) did not. The mPFS was 16.1 months for patients with a PPI versus 22.2 months for those without (p = 0.26). In the ribociclib group, 44 patients used a PPI and 61 did not use a PPI. The median PFS was comparable between patients receiving PPIs and those not receiving PPIs (19.3 months and 20.7 months, respectively). Poor PFS was associated with liver metastasis, brain metastasis, and high Ki-67. Conclusion: Concomitant use of PPIs with ribociclib or palbociclib did not affect the efficacy of either CDK4/6 inhibitor. PPIs can be administered alongside these medications when clinically indicated. (c) 2024 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000542693
dc.identifier.issn0030-2414
dc.identifier.issn1423-0232
dc.identifier.pmid39586283en_US
dc.identifier.scopus2-s2.0-85214356411en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1159/000542693
dc.identifier.urihttps://hdl.handle.net/11468/29670
dc.identifier.wosWOS:001387957400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectBreast canceren_US
dc.subjectDrug interactionsen_US
dc.subjectPalbocicliben_US
dc.subjectProton pump inhibitorsen_US
dc.subjectRibocicliben_US
dc.titleConcomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu